Evaluation of antitumor activity of rubomycin deposited in absorbable polymeric microparticles

Area of Science:

• Oncology
• Materials Science
• Pharmacology

Background:

• Rubomycin is a chemotherapy drug with known antitumor properties.
• Developing effective drug delivery systems is crucial for enhancing therapeutic efficacy and minimizing side effects.
• Absorbable polymeric matrices offer potential for controlled drug release and localized administration.

Purpose of the Study:

• To develop and evaluate an experimental dosage form of rubomycin encapsulated in polyhydroxybutyrate microparticles.
• To assess the antitumor efficiency of this novel rubomycin formulation against Ehrlich ascitic carcinoma in a preclinical mouse model.

Main Methods:

• Rubomycin was incorporated into an absorbable polyhydroxybutyrate matrix to create microparticles.
• The antitumor activity of the rubomycin-loaded microparticles was evaluated in laboratory mice bearing transplanted Ehrlich ascitic carcinoma.
• Key efficacy parameters included tumor growth inhibition and animal survival rates.

Main Results:

• The rubomycin-loaded polyhydroxybutyrate microparticles demonstrated pronounced antitumor activity.
• The formulation effectively inhibited the proliferative activity of Ehrlich ascitic carcinoma.
• Significant improvements in the survival of tumor-bearing mice were observed.

Conclusions:

• Rubomycin encapsulated in polyhydroxybutyrate microparticles represents a promising experimental dosage form for cancer therapy.
• This novel formulation exhibits significant efficacy in inhibiting tumor growth and improving survival.
• The developed dosage form is suitable for local injection, offering a potential new strategy for cancer treatment.